Cost-effectiveness of Enhanced Depression Care After Acute Coronary Syndrome: Results From the Coronary Psychosocial Evaluation Studies Randomized Controlled Trial

Ladapo, Joseph A.; Shaffer, Jonathan A.; Fang, Yixin; Ye, Siqin; Davidson, Karina W.

Depression following an acute coronary syndrome (ACS) affects 2 in 5 patients and is one of the most important psychosocial predictors of a poor cardiovascular prognosis.1 In the Coronary Psychosocial Evaluation Studies (COPES) randomized controlled trial, we compared the effectiveness of enhanced depression care, which comprised patient preference for problem-solving psychotherapy, antidepressant use, or both, through the use of a stepped-care algorithm, with usual care in patients with ACS and persistent depressive symptoms 3 months after discharge.2 The 6-month trial demonstrated that enhanced depression care improved patient satisfaction with treatment and reduced depressive symptoms. However, the intervention's impact on health-related quality of life, health care utilization, and cost-effectiveness has not been evaluated. To help bridge this gap and inform decision making, we undertook a cost-effectiveness analysis of enhanced depression treatment in patients with ACS and persistent depressive symptoms using results from the COPES trial.


  • thumnail for Ladapo_Arch_Intern_Med_2012_PMC.pdf Ladapo_Arch_Intern_Med_2012_PMC.pdf application/pdf 33.1 KB Download File

Also Published In

Archives of Internal Medicine

More About This Work

Academic Units
Center for Behavioral Cardiovascular Health
American Medical Association
Published Here
July 10, 2016